Recruiting

Continuous Glucose Monitoring

Sponsor:

Vanderbilt University Medical Center

Code:

NCT06852950

Conditions

Type 2 Diabetes Mellitus (T2DM)

Type 1 Diabetes Mellitus (T1DM)

Hyperglycemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Libre 3 Plus Continuous Glucose Monitor

Dexcom G7 Continuous Glucose Monitor

Study Details

Brief summary:

This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.

Conditions

Type 2 Diabetes Mellitus (T2DM)

Type 1 Diabetes Mellitus (T1DM)

Hyperglycemia

Study ID

NCT06852950

Start date

Mar 9, 2025

Status verified date

Mar, 2026

Completion date

Jan, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
  • Able to give informed consent
  • Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
  • POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
  • Need glucose readings greater than or equal to one time per day
  • Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone

Exclusion Criteria:

  • Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
  • Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
  • Received chemotherapy during current hospitalization
  • Planning on major surgery within 10-15 days
  • Hemodialysis or peritoneal dialysis
  • Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
  • Vitamin C use of more than 500 milligrams per day
  • Hydroxyurea use
  • Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
  • Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
  • Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
  • Skin allergy to adhesives

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Libre 3 Plus Continuous Glucose Monitor

Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.

experimental: Dexcom G7 Continuous Glucose Monitor

Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.

Interventions

Libre 3 Plus Continuous Glucose Monitor

Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.

Dexcom G7 Continuous Glucose Monitor

Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.

Primary outcome measure

  • Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system [ Time Frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge ]
  • Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care [ Time Frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge ]
  • Questionnaire responses regarding patient familiarity with continuous glucose monitoring [ Time Frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge ]

Central Contacts and Locations

Central contacts

Angel Morvant, MD

615-343-8332angel.morvant@vumc.org

Locations

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Angel Morvant, MD

(615) 343-8332angel.morvant@vumc.org

Principal Investigator:

Angel Morvant, MD

More Information

Sponsor

Vanderbilt University Medical Center

Last update posted

Mar 5, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Vanderbilt University Medical Center on 2026-03-05.